High-level expression of forkhead-box protein A1 in metastatic prostate cancer

Rohit K. Jain, Rutika J. Mehta, Harikrishna Nakshatri, Muhammad Idrees, Sunil Badve

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Aims: Expression of forkhead-box protein A1 (FOXA1), a transcription factor important for normal development of the prostate gland, is thought to be controlled by steroid hormones and GATA3. The aim of this study was to investigate the expression and potential role of FOXA1 and GATA3 transcription factors as prognostic factors in prostate cancer. Methods and results: Expression of FOXA1, GATA3 and androgen receptor (AR) was retrospectively analysed by immunohistochemistry in a series of 80 primary tumours and 28 metastatic prostate cancers, including 15 matched paired samples. Nuclear AR expression did not significantly differ between primary and metastatic tumours. High-level nuclear FOXA1 expression was seen in 19% of primary and 89% of metastatic tumours (P<0.0001). FOXA1 expression correlated positively with tumour size, extraprostatic extension, angiolymphatic invasion, AR and lymph node metastases at diagnosis, but did not correlate with age, T stage, Gleason score, presence of prostatic intraepithelial neoplasia or multifocality, seminal vesicle or perineural invasion, or surgical excision margin status. Expression of GATA3 was not seen in either normal epithelium or tumour. Conclusions: Our preliminary analyses suggest that high-level FOXA1 expression is associated with the development of metastatic prostate cancer. If these data are confirmed, FOXA1 expression could be used to classify patients at higher risk for metastases.

Original languageEnglish
Pages (from-to)766-772
Number of pages7
JournalHistopathology
Volume58
Issue number5
DOIs
StatePublished - Apr 2011

Fingerprint

Hepatocyte Nuclear Factor 3-alpha
Prostatic Neoplasms
Androgen Receptors
Neoplasms
GATA3 Transcription Factor
Prostatic Intraepithelial Neoplasia
Neoplasm Metastasis
Neoplasm Grading
Seminal Vesicles
Cytoplasmic and Nuclear Receptors
Prostate
Transcription Factors
Epithelium
Lymph Nodes
Immunohistochemistry
Steroids
Hormones

Keywords

  • AR
  • FOXA1
  • GATA3
  • Metastases
  • Prostate cancer

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

High-level expression of forkhead-box protein A1 in metastatic prostate cancer. / Jain, Rohit K.; Mehta, Rutika J.; Nakshatri, Harikrishna; Idrees, Muhammad; Badve, Sunil.

In: Histopathology, Vol. 58, No. 5, 04.2011, p. 766-772.

Research output: Contribution to journalArticle

@article{058e2284fee7485593e95a04808561c9,
title = "High-level expression of forkhead-box protein A1 in metastatic prostate cancer",
abstract = "Aims: Expression of forkhead-box protein A1 (FOXA1), a transcription factor important for normal development of the prostate gland, is thought to be controlled by steroid hormones and GATA3. The aim of this study was to investigate the expression and potential role of FOXA1 and GATA3 transcription factors as prognostic factors in prostate cancer. Methods and results: Expression of FOXA1, GATA3 and androgen receptor (AR) was retrospectively analysed by immunohistochemistry in a series of 80 primary tumours and 28 metastatic prostate cancers, including 15 matched paired samples. Nuclear AR expression did not significantly differ between primary and metastatic tumours. High-level nuclear FOXA1 expression was seen in 19{\%} of primary and 89{\%} of metastatic tumours (P<0.0001). FOXA1 expression correlated positively with tumour size, extraprostatic extension, angiolymphatic invasion, AR and lymph node metastases at diagnosis, but did not correlate with age, T stage, Gleason score, presence of prostatic intraepithelial neoplasia or multifocality, seminal vesicle or perineural invasion, or surgical excision margin status. Expression of GATA3 was not seen in either normal epithelium or tumour. Conclusions: Our preliminary analyses suggest that high-level FOXA1 expression is associated with the development of metastatic prostate cancer. If these data are confirmed, FOXA1 expression could be used to classify patients at higher risk for metastases.",
keywords = "AR, FOXA1, GATA3, Metastases, Prostate cancer",
author = "Jain, {Rohit K.} and Mehta, {Rutika J.} and Harikrishna Nakshatri and Muhammad Idrees and Sunil Badve",
year = "2011",
month = "4",
doi = "10.1111/j.1365-2559.2011.03796.x",
language = "English",
volume = "58",
pages = "766--772",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - High-level expression of forkhead-box protein A1 in metastatic prostate cancer

AU - Jain, Rohit K.

AU - Mehta, Rutika J.

AU - Nakshatri, Harikrishna

AU - Idrees, Muhammad

AU - Badve, Sunil

PY - 2011/4

Y1 - 2011/4

N2 - Aims: Expression of forkhead-box protein A1 (FOXA1), a transcription factor important for normal development of the prostate gland, is thought to be controlled by steroid hormones and GATA3. The aim of this study was to investigate the expression and potential role of FOXA1 and GATA3 transcription factors as prognostic factors in prostate cancer. Methods and results: Expression of FOXA1, GATA3 and androgen receptor (AR) was retrospectively analysed by immunohistochemistry in a series of 80 primary tumours and 28 metastatic prostate cancers, including 15 matched paired samples. Nuclear AR expression did not significantly differ between primary and metastatic tumours. High-level nuclear FOXA1 expression was seen in 19% of primary and 89% of metastatic tumours (P<0.0001). FOXA1 expression correlated positively with tumour size, extraprostatic extension, angiolymphatic invasion, AR and lymph node metastases at diagnosis, but did not correlate with age, T stage, Gleason score, presence of prostatic intraepithelial neoplasia or multifocality, seminal vesicle or perineural invasion, or surgical excision margin status. Expression of GATA3 was not seen in either normal epithelium or tumour. Conclusions: Our preliminary analyses suggest that high-level FOXA1 expression is associated with the development of metastatic prostate cancer. If these data are confirmed, FOXA1 expression could be used to classify patients at higher risk for metastases.

AB - Aims: Expression of forkhead-box protein A1 (FOXA1), a transcription factor important for normal development of the prostate gland, is thought to be controlled by steroid hormones and GATA3. The aim of this study was to investigate the expression and potential role of FOXA1 and GATA3 transcription factors as prognostic factors in prostate cancer. Methods and results: Expression of FOXA1, GATA3 and androgen receptor (AR) was retrospectively analysed by immunohistochemistry in a series of 80 primary tumours and 28 metastatic prostate cancers, including 15 matched paired samples. Nuclear AR expression did not significantly differ between primary and metastatic tumours. High-level nuclear FOXA1 expression was seen in 19% of primary and 89% of metastatic tumours (P<0.0001). FOXA1 expression correlated positively with tumour size, extraprostatic extension, angiolymphatic invasion, AR and lymph node metastases at diagnosis, but did not correlate with age, T stage, Gleason score, presence of prostatic intraepithelial neoplasia or multifocality, seminal vesicle or perineural invasion, or surgical excision margin status. Expression of GATA3 was not seen in either normal epithelium or tumour. Conclusions: Our preliminary analyses suggest that high-level FOXA1 expression is associated with the development of metastatic prostate cancer. If these data are confirmed, FOXA1 expression could be used to classify patients at higher risk for metastases.

KW - AR

KW - FOXA1

KW - GATA3

KW - Metastases

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=79954568222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954568222&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2011.03796.x

DO - 10.1111/j.1365-2559.2011.03796.x

M3 - Article

C2 - 21401706

AN - SCOPUS:79954568222

VL - 58

SP - 766

EP - 772

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 5

ER -